Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XFB19 in Healthy Adult Volunteers
NCT05361733Phase 1Recruiting
- Sponsor
- Xfibra, Inc.
- Start
- Feb 2026
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute respiratory distress syndrome (ARDS), Liver cirrhosis (LC) and idiopathic pulmonary fibrosis (IPF) comparing XFB19 administered SC with Placebo (2 arms). Primary endpoints: Adverse Events up to 10 days, Heart Rate up to 10 days and 9 more. Started Feb 2026; status: recruiting.
02
Drugs
XFB19
03
Conditions
acute respiratory distress syndrome (ARDS)Liver cirrhosis (LC)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05361733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361733.